Tuesday, February 23, 2016 8:34:27 AM
Source: Business Wire
-Six Orange Book Listed Patents Running from 2026-2033-
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (“Eagle” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,265,831, which pertains to liquid bendamustine hydrochloride (HCl) formulations. The patent issued today expires on January 28, 2031. This new patent, along with five previously issued Patents (Nos. 8,609,707, 8,791,270*PED, 9,000,021, 9,034,908, and 9,144,568), further expands and protects Eagle’s bendamustine HCI intellectual property estate. This grant brings the total number of Orange Book listed patents to six, with this latest patent to be included shortly.
“Eagle continues to strengthen its bendamustine patent portfolio with now six Orange Book listed patents running from 2026-2033 and several more pending. The issuance of this new patent supports the long-term earnings potential of the bendamustine franchise products and further protects its longevity. Given the nature of our patent portfolio, the Company believes that it will be very difficult for any ANDA filers to design around these patents,” said Scott Tarriff, President and Chief Executive Officer of Eagle Pharmaceuticals.
Under a February 2015 exclusive license agreement for BENDEKA™ (bendamustine hydrochloride) Injection, Teva Pharmaceuticals is responsible for all U.S. commercial activities for the product including promotion and distribution.
The following table lists the patents for liquid bendamustine hydrochloride (HCl) formulations:
U.S. Patent No. Patent Expiration
8,609,707 8/11/2031
8,791,270*PED (owned by Teva Pharmaceutical
Industries Ltd.)
7/12/2026
9,000,021 3/15/2033
9,034,908 3/15/2033
9,144,568 3/15/2033
9,265,831 1/28/2031
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the company’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as “will,” “may,” “intends,” “anticipate(s),” “plan,” “enables,” “potentially,” “entitles,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future events including, but not limited to: difficulties or delays in manufacturing; the enforceability or defense of intellectual property rights against third parties; the success of Eagle’s commercial relationship with Teva and the companies’ ability to successfully work together; the availability and pricing of third party sourced products and materials, and products licensed to third-parties for promotion and distribution; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; and other factors that are discussed in Eagle’s Annual Report on Form 10-K for the year ended September 30, 2014, and its other filings with the U.S. Securities and Exchange Commission. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond Eagle’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks include, but are not limited to risks described in Eagle’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160223006008/en/
Investor Relations for Eagle Pharmaceuticals, Inc.:
In-Site Communications, Inc.
Lisa M. Wilson, 212-452-2793
lwilson@insitecony.com
Recent EGRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 12:20:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 01:08:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:29:46 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/10/2024 09:27:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:49:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 09:40:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 12:35:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 01:23:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:44:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:09:16 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/14/2024 10:09:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 08:53:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:50:12 PM
- Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX • PR Newswire (US) • 02/09/2024 10:45:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/07/2024 02:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 10:09:59 PM
- The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) • PR Newswire (US) • 02/02/2024 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) • PR Newswire (US) • 01/26/2024 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) • PR Newswire (US) • 01/19/2024 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 11:56:43 AM
- Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio • GlobeNewswire Inc. • 01/18/2024 11:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 12:00:35 PM
- The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) • PR Newswire (US) • 01/12/2024 10:45:00 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM